Surgeon Experience ReSTOR A +4

This study has been completed.

First Received: August 8, 2008 Last Updated: August 11, 2008 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00733512

Purpose

To collect visual outcome data post AcrySof ReSTOR Aspheric +4 implantation from surgeons throughout the USA.

Condition	Intervention	Phase
Cataract	Device: ReSTOR	Phase IV

MedlinePlus related topics: Cataract Surgery

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Visual acuity [ Time Frame: 1 week to 10 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Contrast sensitivity [ Time Frame: 1 week to 10 months ] [ Designated as safety issue: No ]

Enrollment:	267
Study Start Date:	June 2007
Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
ReSTOR AcrySof ReSTOR Aspheric +4 IOL	Device: ReSTOR Patients received AcrySof ReSTOR Aspheric +4 IOL in one or both eyes.

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00733512

Locations

United States, Texas
Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

More Information

No publications provided

Responsible Party:	Alcon Research ( Rick Potvin/Director - Global Scientific Market Affairs Dept )
Study ID Numbers:	M07-019
Study First Received:	August 8, 2008
Last Updated:	August 11, 2008
ClinicalTrials.gov Identifier:	NCT00733512 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Alcon Research:

ReSTOR Aspheric +4 IOL

Study placed in the following topic categories:

Eye Diseases
Cataract
Lens Diseases

Additional relevant MeSH terms:

Eye Diseases
Cataract
Lens Diseases

ClinicalTrials.gov processed this record on May 07, 2009